newsfilter
← Latest News
GlobeNewswire·

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

  • BioStem Technologies (NASDAQ: BSEM) Chair & CEO Jason Matuszewski & COO Andrew Van Vurst exercised options to purchase 250,000 shares each at $2.00 per share.
  • The transactions resulted in a total of 500,000 shares purchased for an aggregate price of approximately $1 million.
  • Matuszewski stated the capital will support expanded sales coverage, hospital formulary inclusion, & inventory for new accounts.
  • Van Vurst noted the funds will assist with inventory & infrastructure to serve new hospital accounts while maintaining production quality.
  • BioStem utilizes proprietary BioRetain, CryoTek, & SteriTek technologies to process perinatal allografts for various clinical specialties.
  • The company holds AATB accreditation for its quality management system, complying with cGTP & cGMP standards.
  • BioStem's product portfolio includes Neox, Clarix, VENDAJE, & American Amnion brands.
  • The press release includes forward-looking statements regarding growth prospects, capital application, & market needs subject to risks like Nasdaq listing compliance & financing availability.